Attention: open in a new window. E-mailPrintPDF
In Q3 of 2019, listed insulin maker Bioton posted a consolidated attributable net loss o PLN7.34m, reducing the loss from PLN18.57m a year before. The operating loss contracted from PLN8.99m…

Order subscription to read this article




Order at
Order from our partners:

Call us:

Find us: